Literature DB >> 33393071

Malignancy-associated membranous nephropathy with PLA2R double-positive for glomeruli and carcinoma.

Itaru Yasuda1, Hirobumi Tokuyama1, Akinori Hashiguchi2, Kazuhiro Hasegawa1, Kiyotaka Uchiyama1, Masaki Ryuzaki1, Marie Yasuda1, Ryuichi Mizuno3, Shigeto Ishidoya4, Shu Wakino5, Hiroshi Itoh1.   

Abstract

Phospholipase A2 receptor (PLA2R) is the most common primary target antigen of idiopathic membranous nephropathy (MN) although PLA2R antibodies are also reported to be present in malignancy-associated MN. However, a case of PLA2R-positive MN secondary to PLA2R-positive carcinoma has not been reported. A 26-year-old Japanese woman presented with general fatigue, fever, and nonproductive cough. Computed tomography demonstrated a left kidney mass with pathologic diagnosis of Xp11.2 translocation renal cell carcinoma (RCC). After the second time of administration with Sunitinib, the patients exhibited significant proteinuria and hypoalbuminemia. Renal biopsy revealed a diagnosis of diffuse MN secondary to RCC. Immunofluorescence staining showed granular patterns positive for immunoglobulin (Ig) G, IgA, and C3c. PLA2R and IgG1-3 were positive, while IgG4 was negative. For the treatment of severe nephrotic syndrome, we attempted steroid therapy without any clinical improvement. Open nephrectomy was performed and surprisingly, RCC was stained for PLA2R with polarity for the basal side. At outpatient follow-up, 4 months after the operation, urinary protein had still persisted, although serum albumin was slightly increased. We report a case of PLA2R-positive MN secondary to PLA2R-positive RCC.

Entities:  

Keywords:  Immunoglobulin G subclass; Membranous nephropathy; Phospholipase A2 receptor; Xp 11.2 translocation renal carcinoma

Year:  2021        PMID: 33393071     DOI: 10.1007/s13730-020-00556-9

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  1 in total

Review 1.  PLA2R1: expression and function in cancer.

Authors:  David Bernard; David Vindrieux
Journal:  Biochim Biophys Acta       Date:  2014-03-22
  1 in total
  2 in total

Review 1.  Primary membranous nephropathy: an endless story.

Authors:  Ponticelli Claudio
Journal:  J Nephrol       Date:  2022-10-17       Impact factor: 4.393

2.  Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.

Authors:  Praveen Ratanasrimetha; Vikas D Reddy; Jaya Kala; Amanda Tchakarov; William F Glass; Pavlos Msaouel; Jamie S Lin
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.